20:38 , Mar 30, 2017 |  BC Innovations  |  Emerging Company Profile

Unlocking liver regeneration

Although many acute and chronic liver diseases eventually cause liver failure, the only approved treatment is liver transplantation. HepaRegeniX GmbH is developing MKK4 inhibitors to unlock the regenerative capacity of endogenous hepatocytes to treat end-stage...
02:37 , Mar 3, 2017 |  BC Week In Review  |  Financial News

Omeicos completes venture financing

On March 1, cardiovascular disease company Omeicos Therapeutics GmbH (Berlin, Germany) raised €8.3 million ($8.8 million) in the first close of a series B round led by Vesalius Biocapital and SMS Company. Existing investors KfW,...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Helmholtz Association, Spero Therapeutics deal

Helmholtz Association’s tech transfer partner, Ascenion, granted Spero exclusive rights to develop and commercialize anti-Pseudomonas aeruginosa compounds. Helmholtz is eligible to receive milestone and royalty payments. Ascenion acquired an undisclosed equity stake in Spero. Helmholtz’s...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Trianta, Helmholtz Zentrum Muenchen, Max Delbrueck Center for Molecular Medicine Berlin-Buch deal

The Max Delbrueck Center and Helmholtz Zentrum Muenchen granted newco Trianta exclusive, worldwide rights to IP and know-how related to technologies to develop personalized dendritic cell vaccines and adoptive T cell therapies. Under the deal,...
07:00 , Sep 23, 2013 |  BioCentury  |  Emerging Company Profile

Tube: Potent payloads

The potency of Tube Pharmaceuticals GmbH 's tubulysin toxin as a conjugate payload could allow the company to target resistant cancers. Tube is developing a polymer-tubulysin conjugate for solid tumors and has out-licensed the toxin...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

Tube Pharmaceutical GmbH, Helmholtz Centre for Infection Research cancer news

Ascenion GmbH, the technology transfer partner of Helmholtz, and investor Austria Wirtschaftsservice formed Tube Pharmaceuticals, a preclinical stage company developing tubulysins to treat cancer. Tubulysins were discovered by researchers at Helmholtz. Ascenion granted Tube exclusive...
07:00 , Jun 16, 2011 |  BC Innovations  |  Strategy

Spinnovator-a German public startup engine

Technology transfer organization Ascenion GmbH and early stage VC firm Vesalius Biocapital aim to bridge the translational gap in Germany with Spinnovator , a joint initiative that will spend up to €40 million ($58.5 million)...
23:25 , May 23, 2011 |  BC Extra  |  Financial News

Ascenion, Vesalius to fund startups in Germany

Technology transfer company Ascenion GmbH (Munich, Germany) and VC Vesalius Biocapital launched a program to provide startup funding to publicly funded research in Germany. The Spinnovator program will provide up to EUR 40 million ($56.1...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Entheogen, Helmholtz Centre for Infection Research neurology news

Ascenion GmbH, the technology transfer partner of Helmholtz, acquired a 2.5% equity stake in Entheogen for an undisclosed sum. Entheogen plans to start a Phase II trial of its lead compound, BOL-148, to treat cluster...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Arthritis Mitogen-activated protein kinase kinase kinase 7 (MAP3K7; TAK1) A study in mice suggests inhibiting MAP3K7 may help treat arthritis. In a mouse model...